Illinois Medicaid - HFSMedicaid · Coverage · Provider Notice · IL · Endocrinology, Internal Medicine, Family Medicine +1 moreMedium impact
PDL Update to Long-Acting Insulins
Act
by Aug 7, 2026
Effective date
Jul 24, 2026
Identified
Aug 8, 2026
Summary
Illinois Medicaid has temporarily moved insulin glargine-yfgn (a biosimilar) to preferred status on the PDL due to an intermittent supply shortage of Lantus SoloStar pens. This change applies to both Fee-For-Service and Managed Care Organization plans effective July 24, 2026. Lantus vials remain unaffected and preferred. The biosimilar preferred status is temporary and will be reversed once the shortage resolves.
Get alerts when payers change rules like this one
We check Illinois Medicaid - HFS and other payers every day and email you when a change matches your specialty and state.
01Billing and clinical teams must update pharmacy benefit management systems and provider ordering workflows to recognize insulin glargine-yfgn (J7309) as preferred for Illinois Medicaid Fee-For-Service and MCO beneficiaries.
02Providers should be notified that Lantus SoloStar pens may face prior authorization or denial due to shortage; insulin glargine-yfgn is the alternative preferred option.
03Monitor Illinois HFS communications for resolution of the shortage and reversion to original PDL status.
04Failure to update may result in delayed claims or unnecessary prior authorization requests.
05Contact Bureau of Professional and Ancillary Services at 877-782-5565 or the applicable MCO for clarification.
Codes mentioned
J7309J7310J7311
Original notice
PDL Update to Long-Acting Insulins
hfs.illinois.gov · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.